IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors

Journal of Immunology

Volumn 184, Issue 5, 2010, Pages 2348-2354

  Zhu, Shiguo ^a   Lee, Dean Anthony ^b   Li, Shulin ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 27; PLASMID DNA; IL27 PROTEIN, MOUSE; INTERLEUKIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL COUNT; CELL INFILTRATION; COLON TUMOR; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ELECTROPORATION; FEMALE; GENE CONSTRUCT; GENE DELIVERY SYSTEM; GENE THERAPY; GENETIC CODE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT INDICATION; ANIMAL; BAGG ALBINO MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; GENE TRANSFER; GENETICS; IMMUNOLOGY; MALE; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; SURVIVAL; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKINS; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TUMOR BURDEN;

EID: 77951923924     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902371     Document Type: Article

References (59)

1. Trinchieri, G. 1994. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84: 4008-4027. (Pubitemid 24371902)
2. Burke, F. 1999. Cytokines (IFNs, TNF-α, IL-2 and IL-12) and animal models of cancer. Cytokines Cell. Mol. Ther. 5: 51-61.
3. Golab, J., and R. Zagozdzon. 1999. Antitumor effects of interleukin-12 in preclinical and early clinical studies (Review). Int. J. Mol. Med. 3: 537-544.
4. Rakhmilevich, A. L., K. Janssen, J. Turner, J. Culp, and N. S. Yang. 1997. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum. Gene Ther. 8: 1303-1311.
5. Watanabe, Y., K. Kuribayashi, S. Miyatake, K. Nishihara, E. Nakayama, T. Taniyama, and T. Sakata. 1989. Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA 86: 9456-9460.
6. Colombo, M. P., A. Modesti, G. Parmiani, and G. Forni. 1992. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 52: 4853-4857.
7. Forni, G., M. Giovarelli, F. Cavallo, M. Consalvo, A. Allione, A. Modesti, P. Musiani, and M. P. Colombo. 1993. Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy. J. Immunother. Emphasis Tumor Immunol. 14: 253-257.
8. Gansbacher, B., K. Zier, B. Daniels, K. Cronin, R. Bannerji, and E. Gilboa. 1990. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172: 1217-1224.
9. Pardoll, D. M. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13: 399-415.
10. Mackensen, A., A. Lindemann, and R. Mertelsmann. 1997. Immunostimulatory cytokines in somatic cells and gene therapy of cancer. Cytokine Growth Factor Rev. 8: 119-128. (Pubitemid 27299140)
11. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178: 1223-1230.
12. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, et al. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153: 1697-1706.
13. Tannenbaum, C. S., R. Tubbs, D. Armstrong, J. H. Finke, R. M. Bukowski, and T. A. Hamilton. 1998. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161: 927-932.
14. Sarmiento, U. M., J. H. Riley, P. A. Knaack, J. M. Lipman, J. M. Becker, M. K. Gately, R. Chizzonite, and T. D. Anderson. 1994. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab. Invest. 71: 862-873.
15. Cohen, J. 1995. IL-12 deaths: explanation and a puzzle. Science 270: 908.
16. Tare, N. S., S. Bowen, R. R.Warrier, D. M. Carvajal,W. R. Benjamin, J. H. Riley, T. D. Anderson, and M. K. Gately. 1995. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J. Interferon Cytokine Res. 15: 377-383.
17. Tan, J., C. A. Newton, J. Y. Djeu, D. E. Gutsch, A. E. Chang, N. S. Yang, T. W. Klein, and Y. Hua. 1996. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res. 56: 3399-3403. (Pubitemid 26251626)
18. Hanna, E., X. Zhang, J. Woodlis, R. Breau, J. Suen, and S. Li. 2001. Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site. Cancer Gene Ther. 8: 151-157.
19. Lucas, M. L., L. Heller, D. Coppola, and R. Heller. 2002. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol. Ther. 5: 668-675.
20. Chen, Q., N. Ghilardi, H. Wang, T. Baker, M. H. Xie, A. Gurney, I. S. Grewal, and F. J. de Sauvage. 2000. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 407: 916-920.
21. Yoshida, H., S. Hamano, G. Senaldi, T. Covey, R. Faggioni, S. Mu, M. Xia, A. C.Wakeham, H. Nishina, J. Potter, et al. 2001. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 15: 569-578. (Pubitemid 33016442)
22. + T cells. Immunity 16: 779-790.
23. Villarino, A. V., E. Huang, and C. A. Hunter. 2004. Understanding the pro- and anti-inflammatory properties of IL-27. J. Immunol. 173: 715-720.
24. Takeda, A., S. Hamano, A. Yamanaka, T. Hanada, T. Ishibashi, T. W. Mak, A. Yoshimura, and H. Yoshida. 2003. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 170: 4886-4890. (Pubitemid 36554716)
25. Hibbert, L., S. Pflanz, R. De Waal Malefyt, and R. A. Kastelein. 2003. IL-27 and IFN-α signal via Stat1 and Stat3 and induce T-Bet and IL-12Rβ2 in naive T cells. J. Interferon Cytokine Res. 23: 513-522. (Pubitemid 37130074)
26. + T cells through Stat1-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. USA 100: 15047-15052.
27. Pflanz, S., L. Hibbert, J. Mattson, R. Rosales, E. Vaisberg, J. F. Bazan, J. H. Phillips, T. K. McClanahan, R. de Waal Malefyt, and R. A. Kastelein. 2004. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 172: 2225-2231. (Pubitemid 38182370)
28. Artis, D., A. Villarino, M. Silverman,W. He, E. M. Thornton, S. Mu, S. Summer, T. M. Covey, E. Huang, H. Yoshida, et al. 2004. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J. Immunol. 173: 5626-5634.
29. Goldberg, R., Y. Zohar, G. Wildbaum, Y. Geron, G. Maor, and N. Karin. 2004. Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27. J. Immunol. 173: 6465-6471. (Pubitemid 39487808)
30. Owaki, T., M. Asakawa, S. Kamiya, K. Takeda, F. Fukai, J. Mizuguchi, and T. Yoshimoto. 2006. IL-27 suppresses CD28-mediated [correction of medicated] IL-2 production through suppressor of cytokine signaling 3. J. Immunol. 176: 2773-2780. (Pubitemid 43306936)
31. Villarino, A. V., J. S. Stumhofer, C. J. Saris, R. A. Kastelein, F. J. de Sauvage, and C. A. Hunter. 2006. IL-27 limits IL-2 production during Th1 differentiation. J. Immunol. 176: 237-247.
32. Villarino, A., L. Hibbert, L. Lieberman, E. Wilson, T. Mak, H. Yoshida, R. A. Kastelein, C. Saris, and C. A. Hunter. 2003. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19: 645-655. (Pubitemid 37490790)
33. Batten, M., J. Li, S. Yi, N. M. Kljavin, D. M. Danilenko, S. Lucas, J. Lee, F. J. de Sauvage, and N. Ghilardi. 2006. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7: 929-936.
34. Hamano, S., K. Himeno, Y. Miyazaki, K. Ishii, A. Yamanaka, A. Takeda, M. Zhang, H. Hisaeda, T. W. Mak, A. Yoshimura, and H. Yoshida. 2003. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 19: 657-667. (Pubitemid 37490791)
35. Hisada, M., S. Kamiya, K. Fujita, M. L. Belladonna, T. Aoki, Y. Koyanagi, J. Mizuguchi, and T. Yoshimoto. 2004. Potent antitumor activity of interleukin-27. Cancer Res. 64: 1152-1156.
36. Honda, K., K. Nakamura, N. Matsui, M. Takahashi, Y. Kitamura, T. Mizutani, N. Harada, H. Nawata, S. Hamano, and H. Yoshida. 2005. T helper 1-inducing property of IL-27/WSX-1 signaling is required for the induction of experimental colitis. Inflamm. Bowel Dis. 11: 1044-1052.
37. Li, J., B. Gran, G. X. Zhang, A. Rostami, and M. Kamoun. 2005. IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis. J. Neurol. Sci. 232: 3-9.
38. Miyazaki, Y., H. Inoue, M. Matsumura, K. Matsumoto, T. Nakano, M. Tsuda, S. Hamano, A. Yoshimura, and H. Yoshida. 2005. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J. Immunol. 175: 2401-2407. (Pubitemid 41113850)
39. Schmidt, C., T. Giese, B. Ludwig, I. Mueller-Molaian, T. Marth, S. Zeuzem, S. C. Meuer, and A. Stallmach. 2005. Expression of interleukin-12- related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm. Bowel Dis. 11: 16-23.
40. Stumhofer, J. S., A. Laurence, E. H. Wilson, E. Huang, C. M. Tato, L. M. Johnson, A. V. Villarino, Q. Huang, A. Yoshimura, D. Sehy, et al. 2006. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7: 937-945.
41. Chiyo, M., O. Shimozato, L. Yu, K. Kawamura, T. Iizasa, T. Fujisawa, and M. Tagawa. 2005. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer 115: 437-442. (Pubitemid 40663748)
42. + T cells. J. Immunol. 173: 7170-7182.
43. Li, S., X. Zhang, and X. Xia. 2002. Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J. Natl. Cancer Inst. 94: 762-768.
44. Puisieux, I., L. Odin, D. Poujol, P. Moingeon, J. Tartaglia, W. Cox, and M. Favrot. 1998. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity. Hum. Gene Ther. 9: 2481-2492.
45. Li, S., X. Xia, X. Zhang, and J. Suen. 2002. Regression of tumors by IFN-α electroporation gene therapy and analysis of the responsible genes by cDNA array. Gene Ther. 9: 390-397. (Pubitemid 34414037)
46. Li, S., X. Xia, F. M. Mellieon, J. Liu, and S. Steele. 2004. Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy. Mol. Ther. 9: 347-354.
47. Li, S., X. Zhang, X. Xia, L. Zhou, R. Breau, J. Suen, and E. Hanna. 2001. Intramuscular electroporation delivery of IFN-α gene therapy for inhibition of tumor growth located at a distant site. Gene Ther. 8: 400-407. (Pubitemid 32241940)
48. Torrero, M. N., X. Xia, W. Henk, S. Yu, and S. Li. 2006. Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression. Cancer Res. 66: 4461-4467.
49. Pulaski, B. A., and S. Ostrand-Rosenberg. 1998. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493.
50. Wigginton, J. M., E. Gruys, L. Geiselhart, J. Subleski, K. L. Komschlies, J. W. Park, T. A. Wiltrout, K. Nagashima, T. C. Back, and R. H. Wiltrout. 2001. IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J. Clin. Invest. 108: 51-62.
51. + T cell generation with enhanced granzyme B expression by IL-27. J. Immunol. 175: 1686-1693.
52. Li, S., L. Zhang, M. Torrero, M. Cannon, and R. Barret. 2005. Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer. Mol. Ther. 12: 942-949.
53. Torrero, M. N., W. G. Henk, and S. Li. 2006. Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy. Clin. Cancer Res. 12: 257-263.
54. Hunter, C. A., A. Villarino, D. Artis, and P. Scott. 2004. The role of IL-27 in the development of T-cell responses during parasitic infections. Immunol. Rev. 202: 106-114.
55. Brombacher, F., R. A. Kastelein, and G. Alber. 2003. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 24: 207-212. (Pubitemid 36412109)
56. Robinson, D. S., and A. O'Garra. 2002. Further checkpoints in Th1 development. Immunity 16: 755-758.
57. De Giovanni, C.,G.Nicoletti,L. Landuzzi, A. Astolfi, S.Croci,A.Comes, S. Ferrini, R. Meazza, M. Iezzi, E. Di Carlo, et al. 2004. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res. 64: 4001-4009.
58. van Herpen, C. M., R. van der Voort, J. A. van der Laak, I. S. Klasen, A. O. de Graaf, L. C. van Kempen, I. J. de Vries, T. D. Boer,H.Dolstra,R. Torensma, et al. 2008. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int. J. Cancer 123: 2354-2361.
59. Nanni, P., G. Nicoletti, C. De Giovanni, L. Landuzzi, E. Di Carlo, F. Cavallo, S. M. Pupa, I. Rossi, M. P. Colombo, C. Ricci, et al. 2001. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194: 1195-1205.